Skip to search formSkip to main contentSkip to account menu

MK-8033

Known as: MK8033, c-Met Inhibitor MK8033 
An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
SummaryBackground C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression… 
2013
2013
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
Elevated serum levels of hepatocyte growth factor (HGF) and high tumor expression of c-Met are both indicators of poor overall… 
2013
2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with…
This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated… 
2013
2013
A novel cMET inhibitor, MK8033, potentiates the activity of carboplatin/paclitaxel in ovarian cancer cell lines
2010
2010
Abstract 759: Discovery of MK-8033, a highly specific c-Met/Ron dual inhibitor for the treatment of cancer
MK-8033 is a highly specific c-Met/Ron dual inhibitor currently under investigation in Phase I clinical trials for the treatment… 
2009
2009
Abstract #1751: MK-8033, a selective c-Met / Ron inhibitor, suppresses tumor cell growth in vitro and in vivo
Aberrant c-Met activity has been implicated in the pathogenesis of a variety of human tumors and is therefore an attractive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)